In vitro and in vivo evaluation of first-generation carbosilane arene Ru(II)-metallodendrimers in advanced prostate cancer
Authors
Maroto Díaz, Marta; Sanz del Olmo, Natalia; Muñoz Moreno, Laura; Bajo Chueca, Ana María; Carmena Sierra, María José; [et al.]Identifiers
Permanent link (URI): http://hdl.handle.net/10017/46748DOI: 10.1016/j.eurpolymj.2019.01.047
ISSN: 0014-3057
Date
2019-04Embargo end date
2021-04-01Affiliation
Universidad de Alcalá. Departamento de Bioquímica y Biología Molecular; Universidad de Alcalá. Departamento de Biología de Sistemas; Universidad de Alcalá. Departamento de Química Orgánica y Química InorgánicaFunders
Ministerio de Industria, Economía y Competitividad
Instituto de Salud Carlos III
Comunidad de Madrid
Bibliographic citation
European Polymer Journal, 2019, v. 113, p. 229-235
Keywords
Dendrimer
Metallodendrimer
Ruthenium
Cancer therapy
Prostate cancer
Project
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/CTQ2017-86224-P/ES/DENDRONIZACION COMO HERRAMIENTA SINTETICA DE OBTENCION DE NANOSISTEMAS DENDRITICOS ESPECIFICAMENTE DISEÑADOS PARA SU USO EN APLICACIONES BIOMEDICAS
info:eu-repo/grantAgreement/CAM//B2017%2FBMD-3703/ES/NANOSISTEMAS DENDRÍTICOS COMO AGENTES Y VECTORES TERAPÉUTICOS EN DISTINTAS APLICACIONES BIOMEDICAS (II)/NANODENDMED II-CM
info:eu-repo/grantAgreement/CAM//B2017%2FBMD-3733/ES/INMUNIDAD TUMORAL E INMUNOTERAPIA DEL CANCER/IMMUNOTHERCAN-CM
Document type
info:eu-repo/semantics/article
Version
info:eu-repo/semantics/publishedVersion
Rights
Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
© Elsevier, 2019
Access rights
info:eu-repo/semantics/openAccess
Abstract
Background. Prostate cancer is the fifth cause of death among men worldwide. Patients suffering resistant prostate tumor, unresponsive to common treatments, can only be treated with palliative therapy. Materials and methods. Ruthenium(II) carbosilane metallodendrimers containing arene moieties were evaluated as a novel antitumor nanotherapy against resistant prostate cancer. The preclinical evaluation included relevant in vitro, ex vivo and in vivo assays, in an experimental mice model of human prostate cancer. Results. Promising cytotoxic, antiproliferative and antimetastatic behaviors were observed. After treatment with these nanocompounds, mice underwent a significant reduction of tumor volume, in comparison to non-treated animals. Conclusions. The selective antitumor behavior and the lack of toxicity, potentially make ruthenium(II) metallodendrimers promising agents for cancer therapy.
Files in this item
Files | Size | Format |
|
---|---|---|---|
Invitro-GarciaGallego-European ... | 729.5Kb |
|
Files | Size | Format |
|
---|---|---|---|
Invitro-GarciaGallego-European ... | 729.5Kb |
|
Collections
- QUIMINOR - Artículos [236]